BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing Authorisation Variation to the European Medicines Agency (EMA) for a once ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results